Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose co-transporter inhibitors with insulin for treatment of type 1 diabetes (updated October 2020)

Umesh Dashora, Dipesh C Patel, Robert Gregory, Peter Winocour, Ketan Dhatariya, Susannah Rowles, Andrew Macklin, Gerry Rayman, Dinesh Nagi

Abstract


Dapagliflozin (sodium-glucose co-transporter (SGLT-2) inhibitor) and sotagliflozin (SGLT-1/2 inhibitor) are two of the drugs of the SGLT inhibitor class which have been recommended by the National Institute for Health and Care Excellence (NICE) in people with type 1 diabetes with body mass index ≥27 kg/m2. Dapagliflozin is licensed in the UK for use in the NHS while sotagliflozin may be available in future. These and possibly other SGLT inhibitors may be increasingly used in people with type 1 diabetes as new licences are obtained. These drugs have the potential to improve glycaemic control in people with type 1 diabetes with the added benefit of weight loss, better control of blood pressure and more time in optimal glucose range. However, SGLT inhibitors are associated with a higher incidence of diabetic ketoacidosis without significant hyperglycaemia. The present ABCD/Diabetes UK joint updated position statement is to guide people with type 1 diabetes and clinicians using these drugs to help mitigate this risk and other potential complications. Particularly, caution needs to be exercised in people who are at risk of diabetic ketoacidosis due to low calorie diets, illnesses, injuries, starvation, excessive exercise, excessive alcohol consumption and reduced insulin administration, among other precipitating factors for diabetic ketoacidosis.


Keywords


SGLT inhibitors, type 1 diabetes, ketoacidosis, position statement

Full Text:

PDF HTML

References


National Institute for Health and Clinical Excellence (NICE). Dapagliflozin with insulin for treating type 1 diabetes. NICE guidance. London, 2020. https://www.nice.org.uk/guidance/ta597 (accessed 29 August 2020).

National Institute for Health and Clinical Excellence (NICE). Sotagliflozin with insulin for treating type 1 diabetes. NICE guidance. London, 2020. https://www.nice.org.uk/guidance/ta622 (accessed 29 August 2020).

National Institute for Health and Clinical Excellence (NICE). Type 1 diabetes in adults: diagnosis and management. NICE guidance. London, 2016. https://www.nice.org.uk/guidance/ng17 (accessed 29 August 2020).

Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019; 42:1147–54. https://doi.org/10.2337/dc18-2316

Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 2015;66:255–70. https://doi.org/10.1146/annurev-med-051013-110046

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720

Vallon V, Thomson SC. Diabetes mellitus: cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS. Nat Rev Nephrol 2017;13:517–8. https://doi.org/10.1038/nrneph.2017.113

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–34. https://doi.org/10.1056/NEJMoa1515920

Dashora U, Patel DC, Gregory R, et al. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019). Br J Diabetes 2019;19:66–72. https://doi.org/10.15277/bjd.2019.208

Dashora U, Patel D, Gregory R, et al. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes. Br J Diabetes 2018; 18:117–21. https://doi.org/10.15277/bjd.2018.184

Chen Y, Yang K, Marušić A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med 2017;166:128–32. https://doi.org/10.7326/M16-1565

National Institute for Health and Clinical Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guidance. London, 2016. https://www.nice.org.uk/guidance/cg181 (accessed 28 August 2020).

The Healthcare Quality Improvement Partnership. National Diabetes Audit Report 2019. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-quarterly-report-january-to-december-2019#summary (accessed 28 August 2020).

Armstrong AC, Ambale-Venkatesh B, Turkbey E, et al. Association of cardiovascular risk factors and myocardial fibrosis with early cardiac dysfunction in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2017;40:405–11. https://doi.org/10.2337/dc16-1889

Matuleviciene-Anängen V, Rosengren A, Svensson AM, et al. Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart 2017;103:1687–95. https://doi.org/10.1136/heartjnl-2016-311050

Gagnum V, Stene LC, Leivestad T, et al. Long-term mortality and end-stage renal disease in a type 1 diabetes population diagnosed at age 15–29 years in Norway. Diabetes Care 2017;40:38–45. https://doi.org/10.2337/dc16-1213

Sharp P, Kilvert A, Dashora U, et al. Standards of care for management of adults with type 1 diabetes. https://abcd.care/sites/abcd.care/files/site_uploads/Type_1_standards_of_care.pdf (accessed 28 August 2020).

Sharp P, Kilvert A, Dashora U, et al. Standards of care for management of adults with type 1 diabetes updated. https://abcd.care/sites/abcd.care/files/resources/Standards_of_Care_T1DM_ABCD_FINAL.pdf (accessed 28 August 2020).

Nathan DM, for the DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014;37:9–16. https://doi.org/10.2337/dc13-2112

Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 1998;280:140–6. https://doi.org/10.1001/jama.280.2.140

Vella S, Buetow L, Royle P, et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010;53:809–20. https://doi.org/10.1007/s00125-009-1636-9

Staels F, Moyson C, Mathieu C. Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus. Diabetes Obes Metab 2017;19:1463-7. https://doi.org/10.1111/dom.12948

Langford BE, Evans M, Haskins‐Coulter T, et al. Systematic literature review and network meta‐analysis of sodium‐glucose co‐transporter inhibitors vs metformin as add‐on to insulin in type 1 diabetes. Diabetes Obes Metab 2020;22:39–50. https://doi.org/10.1111/dom.13863

Gillani SM, Singh BM. The use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes. Br J Diabetes 2014;14:98–101. https://doi.org/10.15277/bjdvd.2014.022

Dimitrios P, Michael D, Vasilios K, et al. Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis. Curr Diabetes Rev 2020;16:313–26. https://doi.org/10.2174/1573399815666190614141918

Guo H, Fang C, Huang Y, et al. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2016;121:184–91. https://doi.org/10.1016/j.diabres.2016.08.022

Dellepiane S, Nasr MB, Assi E, et al. Sodium glucose cotransporters inhibitors in type 1 diabetes. Pharmacol Res 2018;133:1–8. https://doi.org/10.1016/j.phrs.2018.04.018

Evans M, Hicks D, Patel D, et al. Optimising the benefits of SGLT2 inhibitors for type 1 diabetes. Diabetes Ther 2020;11:37–52. https://doi.org/10.1007/s13300-019-00728-6

Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412–19. https://doi.org/10.2337/dc13-2955

Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015;17:928–35. https://doi.org/10.1111/dom.12494

Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:864–76. https://doi.org/10.1016/S2213-8587(17)30308-X

Famulla S, Pieber TR, Eilbracht J, et al. Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week, randomized, placebo- controlled trial (EASE-1). Diabetes Technol Ther 2017;19:49–60. https://doi.org/10.1089/dia.2016.0261

Rodbard HW, Peters AL, Slee A, et al. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 2017;40:171–80. https://doi.org/10.2337/dc16-1353

Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015;38:2258–65. https://doi.org/10.2337/dc15-1730

Biester T, Aschemeier B, Fath M, et al. Effects of dapagliflozin on insulin- requirement, glucose excretion and s-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. Diabetes Obes Metab 2017;19:1635–9. https://doi.org/10.1111/dom.12975

Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care 2018;41:2552–9. https://doi.org/10.2337/dc18-1087

Huang Y, Jiang Z, Wei Y. Short and medium-term efficacy of sodium glucose cotransporter-2 (SGLT-2) Inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis. Endokrynol Pol 2020;71:325–33. https://doi.org/10.5603/EP.a2020.0034

Chen MB, Xu RJ, Zheng QH, et al. Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: a systematic review and meta-analysis. Medicine 2020;99:e20875. https://doi.org/10.1097/MD.0000000000020875

European Medicines Agency. EMA accepts marketing authorisation variation for Forxiga in adults with type 1 diabetes. Available at: https://www.europeanpharmaceuticalreview.com/news/73381/ema-forxiga-type-1-diabetes/ (accessed 29 August 2018).

Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab 2016;101:3506–15. https://doi.org/10.1210/jc.2016-1451

Saha S, Saha S. A systematic review and meta-analysis of randomised controlled trials, contrasting the safety profile between sodium-glucose cotransporter-2 inhibitors and placebo in type 1 diabetes mellitus patients. Int J Diabetes Metab 2020;25:62–73. https://doi.org/10.1159/000506366

Wang W, Zhang L, Pei X, et al. Evaluation of the safety of SGLT‐2 inhibitors for treating patients with type 1 diabetes. Diabetes Obes Metab 2020;22:1767–76. https://doi.org/10.1111/dom.14092

Zou H, Liu L, Guo J, et al. Sodium‐glucose cotransporter inhibitors as add‐on therapy in addition to insulin for type 1 diabetes mellitus: a meta‐analysis of randomized controlled trials. J Diabetes Investig 2020. https://doi.org/10.1111/jdi.13387

Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 2017;60:1385–9. https://doi.org/10.1007/s00125-017-4301-8

Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687–93. https://doi.org/10.2337/dc15-0843

Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–6. https://doi.org/10.2337/dc15-1251

Perkins BA, Cherney DZ, Partridge H, et al. Sodium glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of concept trial. Diabetes Care 2014;37:1480–3. https://doi.org/10.2337/dc13-2338

Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016;65:1190–5. https://doi.org/10.2337/db15-1356

Herring RA, Shojaee-Moradie F, Garesse R, et al. Full title metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes. Diabetes Care 2020;43:2128–36. https://doi.org/10.2337/dc19-2579

Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512–17. https://doi.org/10.1038/nm.3828

Maruyama H, Hisatomi A, Orci L, et al. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 1984;74:2296–9. https://doi.org/10.1172/JCI111658

Henry RR, Dandona P, Pettus J, et al. Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24 hour continuously monitored mean glucose and fasting β hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab 2017;19:814–21. https://doi.org/10.1111/dom.12882

Li D, Yang JY, Wang T, et al. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Metab 2018;44:410–14. https://doi.org/10.1016/j.diabet.2018.02.001 (accessed 29 August 2020).

Heyward J, Mansour O, Olson L, et al. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PloS One 2020;15:e0234065. https://doi.org/10.1371/journal.pone.0234065

Miyashita S, Kuno T, Takagi H, et al. Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of five randomized controlled trials. Diabetes Res Clin Pract 2020;163:108136. https://doi.org/10.1016/j.diabres.2020.108136

Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D). Diabetes Obes Metab 2018;20:2585–97. https://doi.org/10.1111/dom.13424

GOV.UK. SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes). https://www.gov.uk/drug-safety-update/sglt2-inhibitors-updated-advice-on-increased-risk-of-lower-limb-amputation-mainly-toes (accessed 28 August 2020)

British Cardiovascular Society. Guide for non-diabetes specialist physicians and primary care teams for cardiovascular risk optimisation in patients with type 2 diabetes and atherosclerotic cardiovascular disease (coronary artery disease, peripheral arterial disease, cerebrovascular disease). https://www.britishcardiovascularsociety.org/__data/assets/pdf_file/0021/21963/CaReMe_T2DM_CVD_2020.pdf (accessed 24 October 2020)

European Medicines Agency. SGLT2 inhibitors (previously canagliflozin). https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors-previously-canagliflozin (accessed 2 September 2020).

Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487–93. https://doi.org/10.2337/dci19-0066

US Food and Drugs Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin (accessed 2 September 2020).

Guo M, Ding J, Li J, et al. SGLT2 inhibitors and stroke risk in patients with type 2 diabetes: a systematic review and meta‐analysis. Diabetes Obes Metab 2018;20:1977–82. https://doi.org/10.1111/dom.13295

Zou CY, Liu XK, Sang YQ et al. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. Medicine 2019;98:e18245. https://doi.org/10.1097/MD.0000000000018245

Das L, Dutta P. SGLT2 inhibition and COVID‐19: the road not taken. Eur J Clin Investig 2020;e13339. https://doi.org/10.1111/eci.13339

ClinicalTrials.gov. Dapagliflozin in respiratory failure in patients with COVID-19 (DARE-19). 2020. https://www.clinicaltrials.gov/ct2/show/NCT04350593 (accessed 29 August 2020).




DOI: https://doi.org/10.15277/bjd.2020.265

Refbacks

  • There are currently no refbacks.


The Journal of the Association of British Clinical Diabetologists